Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Vaxxit Logo
Vaxxit CB Rank
1383839
Heat Score
55
Vaxxit is a biopharmaceutical company developing vaccines against HIV.
Founded
obfuscation
Private Roma, Lazio, Italy1-10 www.vaxxit.com
Health Care
Pharmaceutical
Therapeutics
Overview

Vaxxit
Heat Score
55

Growth Score
pts
in past quarter
Heat Score 55
-6 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Vaxxit

CB Rank
1383839
Vaxxit is a biopharmaceutical company developing vaccines against HIV.
Founded
obfuscation
Private Roma, Lazio, Italy1-10 www.vaxxit.com
Health Care
Pharmaceutical
Therapeutics

Key People

Details

Legal Name Vaxxit S.r.l.
Operating Status Active
Company Type For Profit
Founders  Giovanni Cozzone
About the Company
Vaxxit provides vaccines against HIV, herpes simplex virus, and tuberculosis. They also offer therapeutic vaccines for people with HIV on antiretroviral therapy. Their customers contact them through email, mobile, and online applications.
Contact Email info@vaxxit.com
Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

TatImmune
A vaccine candidate designed for therapeutic and preventive use against HIV, currently in Phase II and III clinical trial stages.
HerpesVaxTat
A vaccine candidate based on HSV-1 vectors expressing the Tat protein, targeting herpes simplex virus and tuberculosis, currently completing preclinical safety testing.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials
Market Intelligence
People
View Profiles & Contacts
Headcount 1-10 Employee Profiles 1

Employee Profiles

News
Technology
View Tech Report

Monthly Web Visits

229

IT Spend

$79.7KThis year, Vaxxit is projected to spend $79.7K on IT, according to Aberdeen.

Active Website Tech Count

2Vaxxit is actively using 2 technologies for its website, according to BuiltWith. These include CommonCrawl Top 50m.

Total IP

3The intellectual property of Vaxxit includes 3 registered patents primarily in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Vaxxit's headquarters? Vaxxit is located in Roma, Lazio, Italy.Who are Vaxxit's competitors? Alternatives and possible competitors to Vaxxit may include Sanofi, International AIDS Vaccine Initiative, and  Agenus.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(ccb7a32 1)
|